IQA

IQA is a casein kinase 2 (CK2) inhibitor (IC50 = 0.39 µM). IQA is selective for CK2 over protein kinase A (PKA), glycogen synthase kinase 3beta (GSK3beta), lymphocyte cell-specific protein tyrosine kinase (LCK), dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), and PI3Kgamma (IC50s = 16, 14, 11, 8, and >200 µM, respectively). IQA decreases the viability of Jurkat leukemia cells in a concentration-dependent manner.Formal Name: 5,6-dihydro-5-oxo-indolo[1,2-a]quinazoline-7-acetic acid. CAS Number: 391670-48-7. Synonyms: CGP 029482. Molecular Formula: C17H12N2O3. Formula Weight: 292.3. Purity: >90%. Formulation: (Request formulation change), A solid. Solubility: DMSO: 10 mg/ml. lambdamax: 226, 259, 298 nm. SMILES: O=C(CC(C1=C(N2C3=C4C=CC=C3)C=CC=C1)=C2NC4=O)O. InChi Code: InChI=1S/C17H12N2O3/c20-15(21)9-12-10-5-1-3-7-13(10)19-14-8-4-2-6-11(14)17(22)18-16(12)19/h1-8H,9H2,(H,18,22)(H,20,21). InChi Key: INSBKYCYLCEBOD-UHFFFAOYSA-N.